RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Key Highlights
- ➤PRISM-TAMP enrolled its first patient in borderline resectable pancreatic cancer
- ➤Second patient progressed toward TAMP treatment one week after trial start
- ➤UVM plans to enroll approximately 10 patients in the investigator-initiated trial
- ➤TIGeR-PaC Phase III topline data expected in the second half of 2027
- ➤RenovoRx generated approximately $1.1 million in 2025 RenovoCath sales
Expert Statements
Conor O’Neill, MD, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center
“For patients with borderline resectable pancreatic cancer, treatment before surgery can influence both whether surgery is possible and how completely the tumor can be removed”
Conor O’Neill, MD, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center
“PRISM-TAMP will assess whether delivering chemotherapy directly near the tumor through TAMP before surgery can improve local therapeutic response and surgical outcomes. We are pleased to have enrolled our first patient in this important study.”
Leesa Gentry, Chief Clinical Officer of RenovoRx
“As TAMP becomes more well known in the marketplace, physicians have asked how TAMP could be used in borderline resectable pancreatic cancer and other settings beyond locally advanced pancreatic cancer, which is the focus of our ongoing Phase III clinical trial”
Leesa Gentry, Chief Clinical Officer of RenovoRx
“Enrolling the first PRISM-TAMP patient marks an important step for our IIT program as it moves from concept to clinical execution. These capital-efficient trials enable independent investigators to generate safety and tolerability data of new applications for TAMP, while we remain focused on completing the Phase III TIGeR-PaC trial and reporting topline data in the second half of 2027.”
MOUNTAIN VIEW, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath(®), a patented, FDA-cleared drug-delivery device, announced today that the first patient has enrolled in PRISM-TAMP, “PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP,” an investigator-initiated trial (IIT) sponsored by the University of Vermont (UVM). One week after the IIT began, a second patient is also progressing toward TAMP treatment.
PRISM-TAMP is evaluating the approved chemotherapy gemcitabine delivered through RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) platform, enabled by RenovoCath, as neoadjuvant treatment before surgery in patients with borderline Pancreatic Ductal Adenocarcinoma (PDAC). PRISM-TAMP is the first RenovoRx supported IIT to advance to patient enrollment. UVM plans to enroll approximately 10 patients and is registered on ClinicalTrials.gov (NCT07477418). The primary focus of PRISM-TAMP is to assess PDAC tumor regression, the impact on intraoperative surgical margins following neoadjuvant (pre-surgical) treatment, and overall safety and tolerability.
Get started
Create a free account to read the full story.